Influenza Activity and Vaccine Update

Lisa Grohskopf, MD, MPH

Advisory Committee on Immunization Practices February 22, 2012



National Center for Immunization & Respiratory Diseases

Influenza Division



* This map indicates geographic spread & does not measure the severity of influenza activity



* This map indicates geographic spread & does not measure the severity of influenza activity



Week

Characteristics of Recent Influenza Viruses Tested at CDC

Of 369 U.S. viruses antigenically characterized at CDC since October 1, 2011:

- **58 (16%) Influenza A (H1N1)**
 - 56 (97%) A/California/7/2009-like
- 263 (71%) Influenza A (H3N2)
 - 257 (97%) A/Perth/16/2009-like
- 48 (13%) Influenza B
 - 22 (46%) Victoria lineage; 198 (99%) B/Brisbane/60/2008-like
 - 26 (54%) Yamagata lineage
 - Few B viruses available for testing in US
 - Worldwide most similar to the 2011-2012 vaccine strain





Human Infections with Swine Influenza A Viruses, United States

- 35 human cases of swine influenza A virus infection identified from Dec 2005 – Nov 2011
 - Previously ~ 1 case every 1-2 years
 - Better diagnostics at SHDs
 - Greater awareness
- All triple reassortant swine-origin viruses
- 13 H1N1, 20 H3N2, and 2 H1N2 infections



Reports of Swine-Origin Influenza A(H3N2)v, 2011 (N=12)

- Occurred between 7/2011 11/2011
- 5 states (ME, IA, IN, WV, PA)
- Swine origin H3N2 with matrix (M) gene from A(H1N1)pdm 2009
- Median age 3 years (range 11 months 58 years)
- Mild to moderate influenza-like illness
- Estimated incubation period 2-4 days (range 1-7 days)
- Exposures:
 - 4 with direct exposure to pigs
 - 2 with indirect exposure
 - 6 with potential human-to-human transmission
- Hemagglutinin genes related to H3N2 viruses circulated in 1990s
 - Adults and older children may have limited immunity
- Current seasonal vaccine not anticipated to provide significant protection

Influenza vaccine safety monitoring (2011-12 season)

- Formulation for 2011-12 seasonal influenza vaccine unchanged from 2010-11
- First season of use for intradermal trivalent inactivated influenza vaccine (TIV)
- Second season of use for high-dose TIV
- Monitoring in place in the Vaccine Adverse Event Reporting System (VAERS) and the Vaccine Safety Datalink (VSD)
- No unexpected or new safety concerns detected

Thank You! Acknowledgements:

Lyn Finelli Lynnette Brammer Lenee Blanton Krista Kniss Amber Bishop

Desiree Mustaquim Rosaline Dhara Michael CourterScott Epperson Patrick Glew

Tom Shimabukuro Karen Broder Pedro Moro Frank DeStefano Claudia Velozzi

For more information please contact Centers for Disease Control and Prevention 1600 Clifton Road NE, Atlanta, GA 30333

Telephone, 1-800-CDC-INFO (232-4636)/TTY: 1-888-232-6348 E-mail: cdcinfo@cdc.gov Web: www.cdc.gov



National Center for Immunization & Respiratory Diseases

Influenza Division